


Immunotherapy Institute Announces New Colon Cancer CAR T Cell Therapy Protocol and New Spots for Patients

SAN DIEGO, CA, UNITED STATES, March 22, 2023 /EINPresswire.com/ -- The [Immunotherapy Institute](#) has announced its new [CAR T cell therapy](#) protocol for colon cancer, a personalized targeted immunotherapy that has shown promising results in [recent clinical trials](#). This innovative treatment is not readily available in the US or Canada, where patients might have to wait years before getting access to it. However, in Mexico, patients can get it sooner and take advantage of its benefits.

CAR T cell therapy is a form of immunotherapy that uses a patient's own immune cells to target and destroy cancer cells. It has shown impressive results in various types of cancers. The Immunotherapy Institute's new protocol for colon cancer represents an exciting breakthrough in this field.



The CAR T cell therapy protocol for colon cancer involves extracting T cells from the patient's blood and modifying them in a laboratory to produce chimeric antigen receptors (CARs) that can recognize and bind to specific proteins on the surface of colon cancer cells. The modified CAR T cells are then infused back into the patient's body, where they can recognize and destroy cancer cells that express the targeted protein.

The Immunotherapy Institute is now offering this treatment for cancer patients who have been diagnosed with colon cancer. These patients will receive the new CAR T cell therapy protocol for colon cancer, at a slightly reduced price. The Institute hopes that this will help more patients access this innovative treatment and contribute to the development of better cancer

treatments.

"We are excited to offer this new CAR T cell therapy protocol for colon cancer to patients who need it," said Dr. Ariel Perez, the medical director of the Immunotherapy Institute. "We believe that this personalized targeted immunotherapy has the potential to revolutionize cancer treatment and improve outcomes for patients with solid tumors."

Dr. Ariel Perez, the medical director of the Immunotherapy Institute, has announced the availability of a new CAR T cell therapy protocol for colon cancer patients. This personalized targeted immunotherapy has shown promising results in treating solid tumors, and could potentially bring about a revolution in cancer treatment. Patients who meet the eligibility criteria can consider this therapy as an option at the Immunotherapy Institute.

Patients who are interested in participating in the CAR T cell therapy protocol for colon cancer can contact the Immunotherapy Institute for more information. They will undergo a screening process to determine their eligibility for the therapy, and those who are selected will receive the treatment at the Institute's state-of-the-art facilities in Mexico.

The Immunotherapy Institute is a leading center for cancer treatment and research, with a mission to provide patients with the latest and most advanced cancer therapies. It has a team of world-class scientists and physicians who are dedicated to developing new and effective treatments for cancer. The Institute is committed to advancing the field of immunotherapy and improving outcomes for cancer



patients around the world.

The Immunotherapy Institute's new CAR T cell therapy protocol for colon cancer represents a significant advance in cancer treatment, and its availability in Mexico provides a much-needed option for patients who might have to wait years to access this therapy in the US or Canada. By offering this treatment for patients who have been recently diagnosed or have been struggling with cancer for a while, the Institute hopes to contribute to the development of better cancer treatments and improve outcomes for cancer patients worldwide.

Gabriela Rodriguez

Immunotherapy Institute

+1 619-832-2230

gabriela@immunotherapyinstitute.com

Visit us on social media:

[Facebook](#)

[Instagram](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/623481135>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.